Tenax Therapeutics closed at $1.81 on Nov 4, down 1.63%, 90.1% below its 52-week closing high. Volume of 1.2M shares was 0.60× its 20-day average (below normal).
Split-adjusted performance: -6.2% over one month, -84.9% over six months, -74.8% over one year.
Short interest was 7.2M shares at the Oct 15 settlement (20.4% of float, 3.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TENXTenax Therapeutics | $1.81 | −1.63% | −84.9% | — | — | — | $67.7M | |
| CPIXCumberland Pharmaceuticals | $4.44 | +3.02% | +1.6% | −56.3% | −2569.0% | — | $66.5M | Compare |
| CRBPCorbus Pharmaceuticals Holdings | $3.57 | −7.75% | −67.3% | — | — | — | $69.0M | Compare |
| CINGCingulate | $4.56 | −3.39% | −14.4% | — | — | — | $66.3M | Compare |
| RANIRani Therapeutics Holdings | $0.5728 | +3.06% | −40.3% | — | −432.7% | — | $66.1M | Compare |
| FBIOFortress Biotech | $1.97 | +1.55% | −22.7% | +14.0% | −13.2% | 0.6 | $65.7M | Compare |
| MAIAMAIA Biotechnology | $1.14 | +5.56% | −15.6% | — | — | — | $70.4M | Compare |
| PMVPPMV Pharmaceuticals | $1.33 | −3.99% | −8.6% | — | — | — | $70.8M | Compare |
| TELOTelomir Pharmaceuticals | $0.8750 | −3.85% | −34.7% | — | — | — | $64.5M | Compare |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
